Prescribing information

 

   

LUCENTIS offers patients powerful efficacy across multiple indications1

 

Button image of the words 'DMO' inside of a circle
Button image of the words 'wAMD' inside of a circle
Button image of the words 'PDR' inside of a circle
Button image of the words 'RVO' inside of a circle
Button image of the words 'CNV' inside of a circle
Button image of the words 'ROP' inside of a circle
 

Flexible dosing to adapt to the complex needs

of DMO patients*1

Efficacy in DMO   Dosing & Administration in DMO  


Resources to help you with your LUCENTIS patients

 

Thumbnail image of Education booklet cover

Resources for HCPs

Access the resources for HCPs >

Thumbnail image of Understanding diabetic macular oedema (DMO) cover

Resources for HCPs to share with patients

Access the patient resources >

 


 

We cover a variety of topics about a-VEGF patients, treatment and service impact due to COVID-19 in a variety of webinars and podcasts. 

 

Icon of computer screen displaying various people

Webinar highlights 

Access the webinar highlights >

Image of a microphone icon

Ophthalmology podcasts

Access the ophthalmology podcasts >

 


 

*Once maximum VA is achieved and/or disease activity is stable.

LUCENTIS 0.5 mg is indicated in adults for:1

  • The treatment of neovascular (wet) age-related macular degeneration (AMD)
  • The treatment of visual impairment due to diabetic macular oedema (DMO)
  • The treatment of proliferative diabetic retinopathy (PDR)
  • The treatment of visual impairment due to macular oedema secondary to retinal vein occlusion (branch RVO or central RVO)
  • The treatment of visual impairment due to choroidal neovascularisation (CNV).

LUCENTIS 0.2 mg is indicated in preterm infants for:1

The treatment of retinopathy of prematurity (ROP) with zone I (stage 1+, 2+, 3 or 3+), zone II (stage 3+) or AP-ROP (aggressive posterior ROP) disease.

AMD, age-related macular degeneration; AP-ROP, aggressive posterior ROP; BRVO, branch retinal vein occlusion; CNV, choroidal neovascularisation; CRVO, central retinal vein occlusion; DMO, diabetic macular oedema; HCP, healthcare professional; PDR, proliferative diabetic retinopathy; ROP, retinopathy of prematurity; RVO, retinal vein occlusion; VA, visual acuity; VEGF, vascular endothelial growth factor.

 

Reference

  1. LUCENTIS® (ranibizumab) Summary of Product Characteristics, July 2020.
Rate this content: 
No votes yet
UK | May 2021 | 110674
×

Ask Speakers

×

Medical Information Request

Adverse events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard. Adverse events should also be reported to Novartis via [email protected] or online through the pharmacovigilance intake (PVI) tool at www.report.novartis.com
If you have a question about the product, please contact Medical Information on 01276 698370 or by email at [email protected]